Since the early 1980s, there has been clinical data demonstrating the effects of beta-adrenergic agonist on lipid levels. Terbutaline was shown to raise HDL-c levels in healthy subjects after just two weeks of treatment ([@bb0015]). This data in conjunction with other trials which revealed that beta-blockers lowered HDL-c and raised LDL-c as well as triglycerides ([@bb0010]), supported the hypothesis that stimulation of the beta-2 receptor could result in favorable lipid changes. [@bb0030] found that albuterol administration was associated with favorable changes in the serum lipid profile with significant lowering of LDL-c and increases in HDL-c in a small human trial without marked impairment of glucose tolerance or its physiologic determinants ([@bb0030]). [@bb0040] of *EBioMedicine* found that another selective beta-2 agonist, R-bambuterol also significantly lowered LDL-c in a relatively small healthy volunteer population ([@bb0040]). Since the racemic mixture of bambuterol was not effective in modifying the lipid levels, this suggests that there may be inhibitory effects between R and S bambuterol on the beta-2 receptors that regulate lipoprotein metabolism, Therefore, there is compelling hypothesis generating human data that selective beta-2 agonist may have beneficial effects on lipid metabolism.

Beta-2 agonism stimulates intracellular cAMP, which regulates a number of pathways involved in lipid and glucose metabolism. Sterol regulatory element-binding proteins (SREBPs) are major transcription factors regulating the biosynthesis of cholesterol, fatty acids and triglycerides ([@bb0035]). SREBP is controlled by cAMP, which may explain why beta-2 agonism may affect LDL-c, HDL-c and triglyceride. In addition, cAMP stimulates ABCA1 upregulation, which results in HDL mediated cholesterol efflux from macrophages or hepatocytes ([@bb0005]).

Statin therapy and more recently PCSK9 monoclonal antibodies have demonstrated robust efficacy for lowering LDL-c but there remains significant unmet medical need especially for patients that are refractory or intolerant to these treatment. A recent study, found that of 647 patients with coronary heart disease prescribed statins, about 20% failed to have a significant LDL-lowering response to treatment, and instead saw LDL-cholesterol levels increased 6.2%, compared to a drop of 44.5% among those who responded to the treatment ([@bb0025]). In addition, approximately 10% of dyslipidemic patients are statin intolerant ([@bb0020]). SREBP is an important target for novel drug development and this new clinical data by Ye and colleagues may provide helpful insights into role of beta-2 agonism in lipid metabolism which may provide another class of agents that address an unmet clinical need in patients with dyslipidemia ([@bb0040]).
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